Recursion Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Najat Khan
- Full Time Employees
- 600
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 41 South Rio Grande Street Salt Lake City UT United States of America 84101
- IPO Date
- Apr 16, 2021
- CIK
- 0001601830
- Website
- recursion.com
- Similar Companies
- Business
- Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company specializing in AI-driven drug discovery and development. The company offers an advanced drug discovery platform called the Recursion Operating System (Recursion OS), which integrates machine learning, automation, and large-scale biological and chemical datasets to accelerate the identification and development of novel drug candidates. Its product portfolio includes a pipeline of clinical and preclinical drug candidates targeting oncology and rare diseases, such as REC-617, an oral CDK7 inhibitor for advanced solid tumors, REC-1245, a potential first-in-class RBM39 degrader, REC-4881 for familial adenomatous polyposis, and REC-3964, a potential first-in-class Clostridioides difficile infection toxin B inhibitor. The company also develops biological maps including neuroscience phenomaps and owns proprietary datasets spanning phenomics, transcriptomics, proteomics, and patient data, supported by its automated wet lab platform. Recursion operates globally with key partnerships including Roche/Genentech, Sanofi, Bayer, and Merck KGaA. It was founded in 2013 and is headquartered in Salt Lake City, Utah. Recent major developments include acquiring full rights to the REV102 oral ENPP1 inhibitor program from Rallybio for treating hypophosphatasia, aiming to develop the first oral disease-modifying treatment for the rare genetic disorder. In 2024-2025, Recursion executed a significant business combination with Exscientia, enhancing its platform capabilities by integrating precision chemistry into drug design cycles. The company has streamlined its pipeline by discontinuing or pausing several late-stage drug programs as part of cost reduction and strategic reprioritization, focusing on six active development programs currently mostly in oncology and rare diseases. It secured milestone payments exceeding $500 million cumulatively from partnerships and maintains a strong cash position with a runway into late 2027. Its latest clinical milestones include promising safety and efficacy data from multiple programs and initiation of new clinical trials in solid tumors, lymphoma, and rare diseases, leveraging its AI-powered platform to innovate drug discovery and development processes. Recursion's industry focus lies in biotech and pharmaceutical sectors, targeting patients with aggressive cancers, rare diseases, and other conditions with high unmet medical needs through its proprietary tech-enabled drug discovery system. The company continues to develop its ecosystem of AI and wet lab capabilities to decode complex biology and accelerate the path to novel therapeutic solutions. Its strategic alliances and technology platform position it as a leading clinical-stage biotech entity advancing a data-driven approach to pharmaceutical innovation.
Recursion Pharmaceuticals, Inc. $RXRX Stake Increased by California State Teachers Retirement System
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America SMID Cap Virtual Conference Transcript
The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It’s Not Tech)
Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech News
RXRX Q2 Earnings Miss Estimates, Revenues Fall Y/Y, Stock Down
Recursion Pharmaceuticals Q2 Earnings Call Highlights
Recursion Pharmaceuticals, Inc. (RXRX) Q2 2026 Earnings Call Transcript
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Misses Revenue Estimates
Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program
Recursion to Participate in Upcoming Investor Conferences
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
3 Stocks With the Most Upside by the End of 2026
Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th
Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider
A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed
Amova Asset Management Americas Inc. Sells 801,804 Shares of Recursion Pharmaceuticals, Inc. $RXRX
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know
Why Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market Today
2 Beaten-Down Stocks That Still Aren't Worth Buying